New biomarker provides personalised treatment options for bladder cancer
Researchers use data science and genomics to help determine best treatment options for specific bladder cancers...
List view / Grid view
Researchers use data science and genomics to help determine best treatment options for specific bladder cancers...
Researchers have developed a new computational method that increases the ability to track the spread of cancer cells from one part of the body to another...
Your comprehensive guide to multiplex and single protein detection...
Genetically-encoded biosensors from Montana Molecular allow for detection of GPCR signalling...
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
Mutations in the protein tau, commonly associated with neurodegenerative disorders, may serve as a novel risk factor for cancer...
The Alzheimer’s Association have published a study wherein a model estimates the lifetime risk of an individual developing Alzheimer’s disease dementia. The risk varies with such factors as age and gender, and crucially takes account of preclinical biological changes.
Researchers create eye neuron network model to study retinal diseases, possible treatment options...
ELRIG (European Laboratory Research & Innovation Group) has announced its first Discovery Technologies meeting, which will take place at Alderley Park, located near Macclesfield in Cheshire.
This whitepaper outlines how advances in real-time live-cell monitoring and analysis methods are addressing these changing needs.
27 April 2018 | By Mitra Biotech
In this webinar, speaker Mark Paris, PhD discussed a recent study evaluating a cohort of HNSCC patient tumours treated with anti-PD1 using CANscript TM;. He also be reviewed the results of this study as a means of investigating predictors of clinical response and identifying mechanisms of resistance.
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.